News List

Wednesday February 17, 2010 2009 revenue totaled €6.7 million

Up 63% on the previous financial year and up 60% at constant forex

Category: Investors

Thursday December 31, 2009 IPSOGEN to hold its Annual General Meeting of Shareholders on February 5, 2010, in Marseilles, France

Notice of Meeting of this Shareholders’ AGM published in the French official legal bulletin (“BALO”).

More

Category: Investors

Tuesday December 08, 2009 IPSOGEN strengthens its Management and Board of Directors

Marseille, 8th December 2009 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company that develops, manufactures and markets tests for leukemia and breast cancer, today announces changes in its board and...

Category: Corporate, Investors

Friday September 18, 2009 Results for the first half of 2009

Buoyant growth in activity: +111%

Another half of significant achievements: strengthening of the product portfolio and record sales growth in the United States

Category: Investors

Monday August 31, 2009 Revenue for the First Half of 2009

Very buoyant growth: +111%

Further intensification of activity in the United States

Category: Investors

Monday June 15, 2009 Ipsogen announces the success of a €2.5 million reserved capital increase

Marseille, June 15th 2009 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a cancer ‘profiler’ that develops, manufactures and markets molecular diagnostic tests for leukemia and breast cancer, today announces that it has...

Category: Investors

Wednesday March 18, 2009 2008 annual results in line with the Company’s development plan

Operating costs under control: almost stable operating loss for revenue of €4.1million, up 62.4%Cash position at end-2008: €13.33 million

More

Category: Investors

Wednesday February 18, 2009 2008 annual revenue over expectations, at €4.1m (+62.4%)

Strong sales growth, markedly in the United States: +208.2%

Category: Investors

Thursday October 09, 2008 2008 Half-Year Results

Results in line with expectations.

A first half-year marked by important advances.

Category: Investors

Saturday October 04, 2008 Ipsogen expands its U.S. market presence through licensing agreement with Quest Diagnostics

Marseille, France, October 6th, 2008

Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and...

Category: Leukemia, Investors